1. Epoprostenol produces vasodilation, inhibits pulmonary arterial smooth muscle cell (PASMC) proliferation, and inhibits platelet aggregation through activation of a single receptor type. Which sequence correctly traces how one receptor interaction generates all three of these pharmacological effects?
A) Epoprostenol binds ETA receptors on PASMCs, activating Gq protein and phospholipase C, raising inositol trisphosphate (IP3) and diacylglycerol (DAG), which together produce vasodilation, antiproliferation, and platelet inhibition via protein kinase C (PKC)
B) Epoprostenol binds beta-2 adrenergic receptors on PASMCs, raising cyclic adenosine monophosphate (cAMP) via Gs protein coupling; cAMP activates protein kinase A (PKA), which phosphorylates myosin light chain kinase to produce vasodilation; platelet inhibition is mediated through a separate thromboxane receptor blockade
C) Epoprostenol binds soluble guanylate cyclase (sGC) directly, generating cyclic guanosine monophosphate (cGMP) that activates protein kinase G (PKG); PKG produces vasodilation by phosphorylating voltage-gated calcium channels, antiproliferation by suppressing Rho kinase, and platelet inhibition by reducing thromboxane A2 synthesis
D) Epoprostenol binds prostacyclin receptors (IP receptors) coupled to the Gs protein, activating adenylyl cyclase and raising intracellular cyclic adenosine monophosphate (cAMP); cAMP activates protein kinase A (PKA), which produces vasodilation by relaxing PASMC contractile machinery, antiproliferation by suppressing PASMC growth signaling, and platelet inhibition by reducing platelet activation — all three effects arising from the same IP receptor–cAMP–PKA cascade
E) Epoprostenol binds IP receptors coupled to Gi protein, lowering cAMP in PASMCs, which paradoxically produces vasodilation by removing the tonic contractile drive; platelet inhibition is mediated separately through direct thromboxane receptor antagonism
ANSWER: D
Rationale:
Epoprostenol, synthetic prostacyclin (prostaglandin I2), binds IP receptors on pulmonary arterial smooth muscle cells (PASMCs) and platelets. IP receptors are coupled to the Gs protein, which upon activation stimulates adenylyl cyclase to generate cyclic adenosine monophosphate (cAMP) from ATP. The resulting rise in intracellular cAMP activates protein kinase A (PKA), and it is PKA phosphorylation of downstream targets that produces all three pharmacological effects from this single receptor-second messenger cascade: vasodilation through relaxation of PASMC contractile machinery (reduced myosin light chain phosphorylation and decreased intracellular calcium), antiproliferation through suppression of PASMC mitogenic signaling pathways, and platelet inhibition through suppression of platelet activation and aggregation. The integration of three distinct therapeutic effects through a single receptor-cAMP-PKA axis is what makes prostacyclin deficiency so consequential in PAH and IP receptor agonism so pharmacologically efficient.
Option A: Option A is incorrect because epoprostenol binds IP receptors coupled to Gs, not ETA receptors coupled to Gq; the IP3/DAG/PKC pathway describes Gq-coupled receptor signaling and is not the mechanism of prostacyclin action.
Option B: Option B is incorrect because epoprostenol does not bind beta-2 adrenergic receptors; although beta-2 receptors are also Gs-coupled and raise cAMP, epoprostenol acts specifically at IP receptors, and platelet inhibition is not mediated by thromboxane receptor blockade but by cAMP-driven suppression of platelet activation.
Option C: Option C is incorrect because epoprostenol does not bind or activate soluble guanylate cyclase; sGC activation generating cGMP describes the mechanism of nitric oxide and riociguat, not prostacyclin.
Option E: Option E is incorrect because IP receptors are coupled to Gs (stimulatory), not Gi (inhibitory); Gi coupling would lower cAMP rather than raise it, which is the opposite of prostacyclin's mechanism, and prostacyclin does not antagonize thromboxane receptors directly.
2. A renal transplant recipient on cyclosporine develops PAH and is started on bosentan. She also uses a combined oral contraceptive pill as her sole method of contraception. Which statement correctly integrates the consequences of bosentan's enzyme induction profile for both co-medications and the required clinical response?
A) Bosentan's induction of CYP3A4 simultaneously accelerates cyclosporine metabolism — risking subtherapeutic immunosuppression and graft rejection — and accelerates ethinylestradiol metabolism — rendering the oral contraceptive pill unreliable for pregnancy prevention; both consequences require active management: cyclosporine levels must be monitored and the dose adjusted upward, and the oral contraceptive must be supplemented with or replaced by a non-hormonal or additional barrier method to meet the two-contraception requirement
B) Bosentan inhibits CYP3A4, raising cyclosporine concentrations and increasing nephrotoxicity risk; oral contraceptive levels are unaffected because ethinylestradiol is metabolized by CYP2D6 rather than CYP3A4
C) Bosentan's CYP2C9 induction lowers cyclosporine levels but does not affect oral contraceptive metabolism; the clinical response is to monitor cyclosporine levels and reduce the bosentan dose if they fall below the therapeutic range
D) Bosentan has no meaningful effect on cyclosporine levels because cyclosporine undergoes predominantly renal elimination rather than hepatic CYP metabolism; the oral contraceptive interaction is the only clinically relevant concern
E) Bosentan raises cyclosporine levels by inhibiting the OATP1B1 transporter responsible for cyclosporine hepatic uptake; oral contraceptive levels are simultaneously raised, creating a risk of hormonal excess rather than contraceptive failure
ANSWER: A
Rationale:
Bosentan is a potent inducer of CYP3A4, the cytochrome P450 isoform responsible for metabolizing both cyclosporine and the ethinylestradiol component of combined oral contraceptive pills. The two clinical consequences unfold in parallel. For cyclosporine: accelerated CYP3A4-mediated hepatic metabolism reduces cyclosporine plasma exposure, risking subtherapeutic immunosuppression and precipitating acute rejection in the transplant recipient; cyclosporine trough levels must be monitored closely and the dose adjusted upward to maintain the therapeutic range. For the oral contraceptive: accelerated ethinylestradiol metabolism reduces plasma hormone concentrations below the threshold required for reliable ovulation suppression, rendering the pill an unreliable contraceptive method; the patient must switch to or add a non-hormonal method to satisfy the mandatory two-contraception requirement of the bosentan REMS program. These consequences are simultaneous and both require active clinical management.
Option B: Option B is incorrect because bosentan is a CYP3A4 inducer rather than inhibitor, so it lowers rather than raises cyclosporine concentrations; ethinylestradiol is in fact a CYP3A4 substrate, so oral contraceptive efficacy is affected.
Option C: Option C is incorrect because cyclosporine is a CYP3A4 substrate rather than CYP2C9, and the mechanism relevant here is CYP3A4 induction; reducing the bosentan dose is not the appropriate response since that would compromise PAH treatment.
Option D: Option D is incorrect because cyclosporine undergoes extensive hepatic CYP3A4-mediated first-pass and systemic metabolism rather than predominantly renal elimination; CYP3A4 induction substantially reduces its exposure.
Option E: Option E is incorrect because bosentan is a CYP3A4 inducer, not an OATP1B1 inhibitor; the OATP1B1 inhibition raising ambrisentan levels is the mechanism of the cyclosporine-ambrisentan interaction, not the bosentan interaction, and bosentan lowers rather than raises both cyclosporine and contraceptive hormone levels.
3. A patient with WHO-FC III PAH is currently on ambrisentan plus sildenafil. After 6 months the team wishes to switch the NO-pathway agent from sildenafil to riociguat in an attempt to achieve better cGMP signaling given evidence of suboptimal response. Which statement correctly applies the combination rules and washout requirements to this specific scenario?
A) Ambrisentan and riociguat cannot be combined because both agents act on the endothelin pathway, and combining them would cause additive endothelin receptor blockade with severe hypotension; the team should add a prostacyclin agent instead
B) The switch is straightforward with no washout required; riociguat can be started the same day sildenafil is stopped because the two agents work by completely different mechanisms and have no pharmacodynamic interaction
C) The switch is not recommended because riociguat and ambrisentan together produce additive cGMP accumulation identical to the riociguat plus sildenafil combination, making ERA plus riociguat combination equally contraindicated
D) The switch requires stopping ambrisentan for 48 hours before starting riociguat, because ambrisentan inhibits the hepatic metabolism of riociguat and a washout of the ERA is required to prevent riociguat toxicity
E) The combination of ambrisentan plus riociguat is pharmacodynamically permitted because they act on distinct pathways (endothelin and NO-cGMP respectively); however, sildenafil must be stopped and a minimum 24-hour washout observed before initiating riociguat, because the prohibited combination is the PDE-5 inhibitor plus riociguat, not the ERA plus riociguat
ANSWER: E
Rationale:
Two combination rules govern this scenario. First, the target combination — ambrisentan plus riociguat — is pharmacodynamically safe and clinically used. Ambrisentan blocks ETA receptors on the endothelin pathway, while riociguat stimulates soluble guanylate cyclase (sGC) on the NO-cGMP pathway; these are mechanistically distinct and the combination does not produce additive cGMP accumulation. ERA plus riociguat is an accepted two-pathway combination in guidelines. Second, the transition requires careful management of the outgoing drug. Sildenafil inhibits PDE-5 to prevent cGMP breakdown, and riociguat stimulates sGC to produce more cGMP; combined, they produce additive cGMP accumulation causing severe potentially fatal hypotension — the absolute contraindication. Sildenafil must therefore be stopped and a minimum 24-hour washout observed (reflecting sildenafil's shorter half-life relative to tadalafil's 48-hour requirement) before the first riociguat dose.
Option A: Option A is incorrect because ambrisentan and riociguat do not act on the same pathway; ambrisentan is an ERA acting on the endothelin pathway and riociguat is an sGC stimulator acting on the NO-cGMP pathway, and their combination does not produce additive ETA blockade.
Option B: Option B is incorrect because same-day initiation of riociguat after stopping sildenafil is unsafe; a minimum 24-hour washout is required to avoid the period of overlapping pharmacodynamic action during which additive cGMP accumulation could cause severe hypotension.
Option C: Option C is incorrect because ERA plus riociguat does not produce additive cGMP accumulation; only PDE-5 inhibitor plus riociguat does, because both act on the cGMP pathway by complementary mechanisms; the ERA acts on a completely different pathway.
Option D: Option D is incorrect because the washout requirement applies to the PDE-5 inhibitor (sildenafil), not to ambrisentan; ambrisentan does not inhibit riociguat's hepatic metabolism, and no ERA washout is required before starting riociguat.
4. A patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3b) requires a prostacyclin-pathway agent. She has no central venous access, has previously discontinued subcutaneous treprostinil after three months due to severe infusion site pain, and has a history of Crohn's disease making oral gastrointestinal tolerability a priority concern. Which treprostinil route and supporting rationale is most appropriate?
A) Continuous intravenous (IV) treprostinil via a newly placed tunneled central catheter, because the IV route eliminates infusion site pain and is the only formulation approved for WHO Group 3b PH-ILD
B) Inhaled treprostinil (Tyvaso), because it avoids infusion site pain and the catheter infection risk of IV therapy, carries lower gastrointestinal adverse effect burden than oral treprostinil, and has an approved indication specifically for PH-ILD based on the INCREASE trial
C) Oral extended-release treprostinil, because it eliminates all infusion-related adverse effects and is the preferred first-line formulation in patients with a history of subcutaneous site intolerance
D) Subcutaneous treprostinil resumed at a lower starting dose with more gradual titration, because site pain universally resolves within 4 to 6 weeks and all patients who discontinued for site pain can be successfully re-initiated with modified titration
E) Inhaled iloprost six to nine times daily, because it shares the inhaled route with inhaled treprostinil and has an equivalent approved indication for PH-ILD based on the INCREASE trial
ANSWER: B
Rationale:
Inhaled treprostinil (Tyvaso) addresses each of this patient's three clinical constraints simultaneously. First, it avoids infusion site pain entirely because it is delivered via nebulization rather than subcutaneous catheter — directly relevant given her prior discontinuation from subcutaneous intolerance. Second, it avoids catheter-related bloodstream infection risk because no central venous access is required, and this patient has no existing central line. Third, its gastrointestinal adverse effect burden is lower than oral extended-release treprostinil, which carries a higher GI adverse effect profile that would be particularly problematic in a patient with Crohn's disease. Crucially, inhaled treprostinil holds an approved indication for WHO Group 3b PH-ILD based on the INCREASE trial, which demonstrated significant improvement in 6MWD and time to clinical worsening in this population — making it both pharmacologically appropriate and the only inhaled treprostinil indication outside Group 1 PAH.
Option A: Option A is incorrect because IV treprostinil requires central venous access (which this patient lacks), carries catheter-related infection risk, and IV treprostinil does not hold a specific PH-ILD indication; the INCREASE trial studied the inhaled formulation.
Option C: Option C is incorrect because oral extended-release treprostinil carries a higher gastrointestinal adverse effect burden than inhaled or parenteral routes, making it a poor choice in a patient with active Crohn's disease; it is not the preferred first-line formulation in this context.
Option D: Option D is incorrect because subcutaneous infusion site pain does not universally resolve with slower titration; a subset of patients experience persistent intolerance requiring route change, and this patient has already demonstrated intolerance severe enough to cause discontinuation — reinstating the same route is not the appropriate management.
Option E: Option E is incorrect because iloprost does not hold an approved indication for PH-ILD; the INCREASE trial studied inhaled treprostinil specifically, and iloprost's six-to-nine-times-daily dosing requirement makes adherence substantially more burdensome than inhaled treprostinil's four-times-daily schedule.
5. Ambrisentan's selective ETA antagonism was designed in part to preserve endothelial ETB receptor function. Which statement correctly connects the ETB receptor's endothelial biology to the theoretical rationale for selective blockade, and accurately characterizes whether this theoretical advantage has translated into clinically superior outcomes?
A) Endothelial ETB receptors mediate vasoconstriction and proliferation identical to ETA receptors; preserving them with selective ETA blockade therefore worsens PAH by leaving a vasoconstricting receptor unopposed, which is why dual blockade with bosentan or macitentan is clinically superior to selective ETA agents
B) Endothelial ETB receptors have no established role in vascular biology; the selective ETA design of ambrisentan was motivated entirely by reducing hepatotoxicity rather than any theoretical receptor-level benefit, and clinical trials confirm no ETB-mediated benefit exists
C) Endothelial ETB receptors mediate ET-1 clearance from the circulation and promote release of the vasodilators prostacyclin and nitric oxide (NO); preserving them with selective ETA blockade theoretically maintains these beneficial actions, but this advantage has not translated into clinically meaningful outcome differences between selective and dual ERA blockade in practice
D) Endothelial ETB receptors mediate ET-1 synthesis rather than clearance; preserving them with selective ETA blockade therefore increases circulating ET-1 levels and worsens vasoconstriction — an unintended consequence that has been demonstrated in outcomes trials comparing selective versus dual blockade
E) Endothelial ETB receptors are functionally identical to smooth muscle ETB receptors and both mediate vasoconstriction; blocking ETA alone while leaving all ETB receptors active provides 50 percent of the vasodilatory benefit of dual blockade at half the receptor occupancy, producing proportionally inferior outcomes in all comparative trials
ANSWER: C
Rationale:
The endothelin receptor type B (ETB) has location-dependent, opposite functions. On pulmonary arterial smooth muscle cells, ETB activation contributes to vasoconstriction, like ETA. On the vascular endothelium, however, ETB activation mediates two beneficial actions: clearance of ET-1 from the pulmonary circulation (reducing the circulating vasoconstrictor burden) and stimulation of prostacyclin and nitric oxide (NO) release (promoting vasodilation). The theoretical rationale for selective ETA blockade with ambrisentan is that it suppresses the vasoconstrictive ETA-mediated smooth muscle signaling while leaving endothelial ETB intact to continue ET-1 clearance and vasodilator release — preserving a physiologically beneficial receptor population. However, despite this mechanistically sound rationale, the theoretical advantage has not produced clinically superior outcomes in PAH compared with dual ETA/ETB blockade with bosentan or macitentan; the two approaches show comparable efficacy in clinical practice, and agent selection is guided by hepatotoxicity profile, drug interactions, and dosing convenience rather than receptor selectivity.
Option A: Option A is incorrect because endothelial ETB receptors mediate ET-1 clearance and vasodilator release rather than vasoconstriction; preserving them is the rationale for selective blockade, and no outcomes trial has demonstrated dual blockade superiority.
Option B: Option B is incorrect because the ETB receptor does have established and well-characterized roles in pulmonary vascular biology — ET-1 clearance and prostacyclin/NO release on the endothelium — and the selective design is at least partly motivated by this receptor-level rationale, not solely by hepatotoxicity concerns.
Option D: Option D is incorrect because endothelial ETB receptors mediate ET-1 clearance rather than synthesis; preserving ETB therefore lowers rather than raises circulating ET-1, and no outcomes trial has demonstrated that selective blockade worsens vasoconstriction.
Option E: Option E is incorrect because endothelial and smooth muscle ETB receptors are not functionally identical; their opposing roles are the basis of the theoretical debate; moreover, clinical trials have not demonstrated proportionally inferior outcomes with selective versus dual blockade.
6. A patient on macitentan for PAH is noted to have a hemoglobin of 10.2 g/dL on routine monitoring, down from 12.8 g/dL at baseline. She is asymptomatic and her reticulocyte count is normal. Which explanation correctly identifies the mechanism responsible for this hemoglobin reduction and distinguishes it from true hematologic toxicity?
A) Macitentan causes direct bone marrow suppression by inhibiting erythropoietin receptor signaling in erythroid progenitor cells, producing a hypoproliferative anemia requiring dose reduction or discontinuation
B) Macitentan causes immune-mediated hemolytic anemia by acting as a hapten on red cell membranes, triggering antibody-mediated destruction; a positive direct Coombs test would confirm the diagnosis
C) Macitentan inhibits intestinal iron absorption through upregulation of hepcidin expression, causing iron-deficiency anemia that requires oral iron supplementation to correct
D) Macitentan's potent vasodilatory effect produces plasma volume expansion and hemodilution, diluting the red cell mass without reducing total erythrocyte number or impairing marrow production; this dilutional anemia — occurring in approximately 8 percent of patients — is a recognized drug effect rather than hematologic toxicity, and the normal reticulocyte count supports hemodilution rather than marrow failure or hemolysis
E) Macitentan causes folate deficiency by competitively inhibiting dihydrofolate reductase in erythroid precursors, producing a megaloblastic anemia with hypersegmented neutrophils and elevated mean corpuscular volume (MCV)
ANSWER: D
Rationale:
Hemoglobin reduction occurs in approximately 8 percent of patients treated with macitentan and is attributed to plasma volume expansion driven by the drug's potent vasodilatory effect. Vasodilation reduces systemic vascular resistance, lowering mean arterial pressure and triggering compensatory fluid retention through the renin-angiotensin-aldosterone system; the resulting increase in plasma volume dilutes the red cell mass, reducing measured hemoglobin concentration without reducing total erythrocyte number, impairing erythropoiesis, or causing red cell destruction. This mechanism — hemodilution — explains why the reticulocyte count remains normal: marrow output is intact because there is no true anemia stimulus. Clinically, this hemoglobin reduction typically does not require intervention and is a recognized expected drug effect rather than a signal of hematologic toxicity. This pattern distinguishes macitentan from drugs that cause anemia through bone marrow suppression (which would reduce the reticulocyte count) or hemolysis (which would raise the reticulocyte count and may produce indirect hyperbilirubinemia).
Option A: Option A is incorrect because macitentan does not suppress erythropoietin receptor signaling or cause hypoproliferative marrow failure; the mechanism is hemodilution, and bone marrow suppression is not a recognized macitentan effect.
Option B: Option B is incorrect because macitentan does not cause immune-mediated hemolytic anemia; hemolysis would produce a raised reticulocyte count, elevated LDH, and positive Coombs test, none of which are expected findings with macitentan.
Option C: Option C is incorrect because macitentan does not inhibit intestinal iron absorption or upregulate hepcidin; iron deficiency is not the mechanism, and this would produce a microcytic hypochromic anemia with low ferritin rather than the dilutional pattern seen here.
Option E: Option E is incorrect because macitentan does not inhibit dihydrofolate reductase; folate deficiency causing megaloblastic anemia is the mechanism of methotrexate and trimethoprim, not ERA therapy.
7. Vasoreactivity testing (VRT) is not performed in all PAH patients — its utility is restricted to a defined clinical population and its result governs a specific treatment pathway. Which statement correctly integrates the appropriate patient selection, the agents used for testing, and the treatment implication of a positive result?
A) VRT is recommended in patients with idiopathic, heritable, or drug-induced PAH who do not have features of advanced right heart failure; testing agents include inhaled nitric oxide (NO), intravenous (IV) epoprostenol, or IV adenosine; a positive response — defined as a fall in mPAP of at least 10 mmHg to below 40 mmHg with maintained or increased cardiac output — qualifies the patient for high-dose calcium channel blocker (CCB) therapy as first-line monotherapy
B) VRT should be performed in all newly diagnosed PAH patients regardless of WHO functional class or etiology; agents used are exclusively oral nifedipine and diltiazem given at high dose; a positive response is defined as any symptomatic improvement at 48 hours
C) VRT is reserved exclusively for WHO Group 4 CTEPH patients to determine eligibility for pulmonary endarterectomy; the testing agent is IV riociguat; a positive response qualifies patients for CTEPH surgical intervention
D) VRT is indicated only in WHO-FC IV patients as a last-resort measure before initiating parenteral prostacyclin; testing agents are inhaled prostacyclin analogues only; a positive response permits deferral of IV therapy in favor of oral agents
E) VRT is performed at the time of right heart catheterization in all five WHO groups of pulmonary hypertension to stratify prognosis; a positive response in any group qualifies the patient for CCB monotherapy regardless of the underlying etiology
ANSWER: A
Rationale:
Vasoreactivity testing is recommended for a specific subgroup: patients with idiopathic PAH, heritable PAH, or drug- and toxin-induced PAH who are being evaluated at right heart catheterization and who do not have clinical features of advanced right heart failure. It is not recommended in associated PAH subtypes (connective tissue disease–associated, congenital heart disease–associated, portopulmonary, or HIV-associated PAH), where acute vasoreactivity rarely predicts sustained CCB response. Approved testing agents include short-acting vasodilators: inhaled nitric oxide (10–20 ppm), IV epoprostenol (dose-escalated protocol), or IV adenosine; these produce rapid, titratable pulmonary vasodilation that reverses quickly if hemodynamic instability occurs. A positive response — defined by all three criteria of a mPAP fall of at least 10 mmHg to an absolute below 40 mmHg with maintained or increased cardiac output — identifies the small minority (approximately 10 percent of idiopathic PAH) who have sustained vasodilatory reserve and who can be treated with high-dose nifedipine, diltiazem, or amlodipine as first-line monotherapy, with markedly better long-term prognosis than non-vasoreactive patients.
Option B: Option B is incorrect because VRT is not indicated in all PAH subtypes, is not performed with oral CCBs (which are too slow and systemic for acute testing), and a positive response requires specific hemodynamic criteria rather than symptomatic assessment at 48 hours.
Option C: Option C is incorrect because VRT is not the tool used to determine CTEPH surgical eligibility; the CTEPH surgical decision is based on imaging, anatomical distribution of disease, and expert surgical assessment; IV riociguat is not a VRT agent and riociguat is not used for acute vasoreactivity testing.
Option D: Option D is incorrect because VRT is not restricted to WHO-FC IV patients; it is most relevant in earlier functional class patients where vasoreactivity is more likely and where CCB monotherapy is a viable option; inhaled prostacyclin analogues are not the standard VRT agents.
Option E: Option E is incorrect because VRT is not performed across all five WHO groups and a positive response does not qualify patients of all etiologies for CCB monotherapy; acute vasoreactivity predicts sustained CCB response almost exclusively in idiopathic, heritable, and drug-induced PAH.
8. A 44-year-old woman is newly diagnosed with idiopathic PAH. She has WHO functional class (WHO-FC) III symptoms, a 6-minute walk distance (6MWD) of 280 meters, NT-proBNP (N-terminal pro-B-type natriuretic peptide) of 850 ng/L, echocardiographic right ventricular (RV) dilation with reduced RV function, and right heart catheterization showing a right atrial pressure (RAP) of 10 mmHg and cardiac index (CI) of 2.3 L/min/m². She is vasoreactivity-negative. Applying the 2022 ESC/ERS three-strata risk model, which risk classification and initial treatment regimen are correct?
A) Low risk; initiate high-dose calcium channel blocker (CCB) monotherapy because vasoreactivity testing should be considered inconclusive in WHO-FC III patients and repeated before ruling out CCB eligibility
B) High risk; initiate upfront triple combination including an ERA, a PDE-5 inhibitor, and parenteral epoprostenol because any WHO-FC III patient with an abnormal echocardiogram is automatically classified as high risk
C) Low risk; no PAH-specific therapy required at this time; repeat right heart catheterization in 6 months to reassess hemodynamics before initiating treatment
D) Intermediate risk; initiate a PDE-5 inhibitor as monotherapy with reassessment at 3 months, adding an ERA only if the patient deteriorates to WHO-FC IV
E) Intermediate risk based on the composite of WHO-FC III, 6MWD below 440 meters, NT-proBNP above 300 ng/L, and RV dysfunction; the recommended initial therapy is upfront dual oral combination — an endothelin receptor antagonist (ERA) plus a PDE-5 inhibitor — as established by the AMBITION trial for treatment-naive intermediate-risk patients
ANSWER: E
Rationale:
Applying the 2022 ESC/ERS three-strata model to this patient's data: WHO-FC III places her at intermediate risk; 6MWD of 280 meters (between 165 and 440 meters) places her at intermediate risk; NT-proBNP of 850 ng/L (above 300 ng/L) is above the low-risk threshold; and RV dilation with reduced RV function is an intermediate-to-high risk echocardiographic finding. RAP of 10 mmHg and CI of 2.3 L/min/m² are consistent with intermediate risk (RAP below 14 mmHg, CI above 2.0 L/min/m²). The composite profile places this patient at intermediate risk. For newly diagnosed intermediate-risk patients (WHO-FC II or III), the 2022 ESC/ERS algorithm recommends upfront dual oral combination therapy — an ERA plus a PDE-5 inhibitor — as the evidence-based standard established by the AMBITION trial. This is not a monotherapy-first scenario. The treatment target is subsequent achievement of low-risk status at 3 to 6 month reassessment.
Option A: Option A is incorrect because low-risk classification requires favorable values across all parameters; this patient has multiple intermediate-risk parameters, and CCB therapy is contraindicated given vasoreactivity-negative testing.
Option B: Option B is incorrect because high-risk classification requires parameters at the high-risk threshold across multiple domains, particularly CI below 2.0 L/min/m² and RAP above 14 mmHg; this patient's hemodynamics are intermediate, not high risk, and upfront triple therapy with parenteral prostacyclin is reserved for high-risk patients.
Option C: Option C is incorrect because this patient clearly has established symptomatic PAH at intermediate risk requiring immediate therapy; withholding treatment and deferring to reassessment is inappropriate and contrary to guidelines.
Option D: Option D is incorrect because sequential monotherapy initiation is not the recommended approach for intermediate-risk PAH; upfront dual combination is indicated based on the AMBITION trial, and deferring the ERA until WHO-FC IV is an outdated sequential strategy.
9. A patient on sildenafil for PAH reports intermittent difficulty distinguishing blue from green, most noticeable in low light. Which mechanistic explanation correctly connects this adverse effect to sildenafil's pharmacology?
A) Sildenafil inhibits PDE-5 in the retinal pigment epithelium, raising cyclic guanosine monophosphate (cGMP) in photoreceptor support cells and impairing retinal pigment recycling, causing irreversible photoreceptor degeneration that progresses with continued therapy
B) Sildenafil inhibits phosphodiesterase-6 (PDE-6), the cGMP-degrading enzyme expressed in retinal rod and cone photoreceptors, at higher drug concentrations; PDE-6 inhibition in cones alters phototransduction cascade signaling and produces transient blue-green color discrimination disturbance, which is a dose-related class effect of PDE-5 inhibitors rather than a sign of retinal toxicity
C) Sildenafil raises cyclic guanosine monophosphate (cGMP) in the optic nerve, increasing intraocular pressure and causing a glaucomatous scotoma that impairs peripheral color vision; patients with pre-existing open-angle glaucoma are at highest risk
D) Sildenafil inhibits PDE-3 in the ciliary body, reducing aqueous humor production and causing lens accommodation dysfunction that impairs near-vision color discrimination; the effect resolves within hours of each dose
E) The visual disturbance is caused by systemic hypotension from pulmonary vasodilation reducing retinal perfusion pressure; it is not a direct pharmacological effect of PDE-5 inhibition on retinal cells and resolves with dose reduction to restore systemic blood pressure
ANSWER: B
Rationale:
Sildenafil is a selective PDE-5 inhibitor, but at higher plasma concentrations it also inhibits phosphodiesterase-6 (PDE-6), a structurally related isoform expressed specifically in retinal photoreceptor outer segments — the rod and cone cells responsible for phototransduction and color vision. PDE-6 is the enzyme that degrades cGMP generated by light-activated guanylate cyclase in the phototransduction cascade; its inhibition by sildenafil alters the normal cGMP dynamics in cones, particularly short-wavelength (blue) cones, producing transient impairment of blue-green color discrimination. This is a dose-dependent class effect of PDE inhibitors with cross-reactivity for PDE-6 and is seen with sildenafil at PAH doses as well as erectile dysfunction doses; it does not indicate retinal degeneration or structural photoreceptor damage and is reversible.
Option A: Option A is incorrect because the mechanism involves PDE-6 in photoreceptors rather than PDE-5 in retinal pigment epithelium, and the effect is transient and reversible rather than a sign of progressive irreversible degeneration.
Option C: Option C is incorrect because sildenafil does not raise intraocular pressure or cause glaucomatous scotoma; the visual effect is a photoreceptor-level phototransduction alteration through PDE-6 inhibition, not a pressure-mediated optic nerve insult.
Option D: Option D is incorrect because sildenafil is selective for PDE-5 with cross-reactivity at PDE-6, not PDE-3; PDE-3 inhibition in the ciliary body is not the mechanism, and lens accommodation dysfunction producing near-vision impairment is not the characteristic visual adverse effect of PDE-5 inhibitors.
Option E: Option E is incorrect because the visual disturbance is a direct pharmacological effect of PDE-6 inhibition in retinal photoreceptors rather than an indirect consequence of systemic hypotension reducing retinal perfusion; it occurs even in patients without hemodynamic changes and does not resolve simply by addressing systemic blood pressure.
10. The shift from sequential monotherapy to upfront combination therapy in PAH rests on both a mechanistic rationale and clinical trial evidence. Which statement correctly integrates the pharmacological basis for combination and the trial that established it as the evidence-based standard?
A) Upfront combination is recommended because the three vasoactive pathways share a common final effector — elevated intracellular calcium — and targeting two pathways simultaneously produces twice the calcium suppression of monotherapy, a purely additive effect confirmed by the SERAPHIN trial
B) Upfront combination is recommended solely on the basis of the AMBITION trial's mortality endpoint; the mechanistic rationale is secondary because all three pathways ultimately raise cAMP through different G-protein subtypes
C) Upfront combination is mechanistically rational because the three vasoactive pathways — prostacyclin-cAMP, endothelin-ETA, and NO-cGMP — are biologically distinct, targeting different molecular mediators and intracellular second messengers; simultaneous targeting produces additive or synergistic vasodilation and antiproliferative effects not achievable with any single agent; the AMBITION trial provided the clinical evidence, demonstrating approximately a 50 percent reduction in clinical failure events with upfront ambrisentan plus tadalafil versus either monotherapy in treatment-naive WHO-FC II/III patients
D) Upfront combination is recommended because prostacyclin and NO both raise cGMP through different routes, making their combination uniquely synergistic; adding an ERA is a secondary consideration that adds minimal incremental benefit over the prostacyclin-NO combination
E) The mechanistic rationale for combination is that blocking one pathway causes compensatory upregulation of the other two, making sequential monotherapy progressively less effective; upfront combination preempts all three compensatory responses simultaneously and was established in the PATENT-1 and CHEST-1 trials
ANSWER: C
Rationale:
The mechanistic case for combination therapy begins with the biological independence of the three targeted pathways. The prostacyclin pathway raises cAMP via IP receptor–Gs–adenylyl cyclase coupling. The endothelin pathway drives vasoconstriction and proliferation through ETA receptor–Gq coupling and downstream calcium signaling; ERAs block this pathway. The NO-cGMP pathway raises cGMP through eNOS-derived NO activating soluble guanylate cyclase; PDE-5 inhibitors and riociguat amplify this signaling. Because these three pathways use different molecular mediators, different second messengers, and different intracellular signaling nodes, their pharmacological targets are non-redundant — blocking or augmenting one does not substitute for targeting another. Simultaneous targeting of two or three pathways therefore produces genuinely additive or synergistic pulmonary vasodilation and antiproliferative effects. The AMBITION trial translated this mechanistic rationale into clinical evidence, demonstrating approximately a 50 percent reduction in the composite of clinical failure events with upfront ambrisentan (ERA) plus tadalafil (PDE-5 inhibitor) versus either agent as monotherapy in 500 treatment-naive WHO-FC II or III patients.
Option A: Option A is incorrect because the three pathways do not share elevated intracellular calcium as a universal final effector — the prostacyclin-cAMP and NO-cGMP pathways lower calcium through kinase-mediated mechanisms rather than raising it, and SERAPHIN was the macitentan monotherapy versus placebo trial, not an upfront combination trial.
Option B: Option B is incorrect because AMBITION did not demonstrate a mortality endpoint; its primary endpoint was a composite of clinical failure events (time to first event); also, the three pathways do not all raise cAMP — the NO pathway raises cGMP, not cAMP.
Option D: Option D is incorrect because prostacyclin raises cAMP and NO raises cGMP — these are distinct second messengers, not two routes to the same molecule; describing their combination as raising cGMP conflates the two pathways.
Option E: Option E is incorrect because compensatory pathway upregulation is a contributing rationale but not the primary mechanistic argument; the primary rationale is pathway non-redundancy enabling additive targeting; and PATENT-1 and CHEST-1 were riociguat monotherapy trials, not upfront combination trials.
11. Selexipag's active metabolite ACT-333679 is described as a selective IP receptor agonist, in contrast to prostacyclin analogues such as treprostinil and iloprost. Which statement correctly connects the receptor selectivity difference to a mechanistically explained tolerability difference between these agents?
A) Selexipag produces fewer adverse effects than prostacyclin analogues because it is orally bioavailable rather than inhaled or infused; the route of administration, not receptor selectivity, is the primary determinant of its superior tolerability
B) Selexipag produces fewer adverse effects because its active metabolite has a shorter half-life than prostacyclin analogues, limiting the duration of receptor activation at each dose; the IP receptor selectivity is pharmacokinetically irrelevant to the adverse effect profile
C) Prostacyclin analogues such as treprostinil produce fewer off-target effects than selexipag because they bind all prostanoid receptor subtypes with equal affinity, distributing their activity broadly rather than concentrating it at the IP receptor where adverse effects arise
D) Prostacyclin analogues such as treprostinil bind not only IP receptors but also other prostanoid receptor subtypes including EP3 and DP receptors; this off-target prostanoid receptor binding contributes to adverse effects such as jaw pain, flushing, and diarrhea that are characteristic of the analogue class; selexipag's active metabolite ACT-333679 binds the IP receptor with high selectivity and minimal off-target prostanoid receptor activity, theoretically reducing these class-specific adverse effects
E) Selexipag and prostacyclin analogues have identical receptor binding profiles at the IP receptor; the tolerability difference between them is entirely explained by differences in plasma protein binding affecting free drug concentrations at non-target tissues
ANSWER: D
Rationale:
Prostacyclin analogues including treprostinil and iloprost are not perfectly selective for the IP receptor. They bind additional prostanoid receptor subtypes — including EP3 receptors (which mediate GI cramping and diarrhea when activated in intestinal smooth muscle) and DP receptors (which contribute to flushing and headache when activated in vascular and mast cell tissues) — to varying degrees depending on the specific analogue. This off-target binding at EP3, DP, and other prostanoid receptors contributes to the characteristic adverse effect profile of prostacyclin analogues: jaw pain with chewing (a well-recognized IP and EP receptor–mediated effect in jaw musculature), flushing, headache, and diarrhea. Selexipag's active metabolite ACT-333679 was designed and characterized as a highly selective IP receptor agonist with minimal activity at other prostanoid receptor subtypes; this selectivity profile reduces off-target prostanoid receptor–mediated adverse effects compared with the non-selective analogues.
Option A: Option A is incorrect because the tolerability advantage is mechanistically rooted in receptor selectivity rather than route of administration; an oral prostacyclin analogue would still produce off-target prostanoid receptor effects regardless of route.
Option B: Option B is incorrect because half-life differences between selexipag and prostacyclin analogues are not the primary explanation for the tolerability difference; receptor selectivity — what receptors the drug binds — is the mechanistic basis, independent of how long the drug remains in circulation.
Option C: Option C is incorrect because it inverts the relationship: prostacyclin analogues produce more off-target effects due to broader prostanoid receptor binding, not fewer; high selectivity for IP receptors (as with selexipag's metabolite) is associated with reduced off-target adverse effects, not increased concentration of adverse effects at the IP receptor.
Option E: Option E is incorrect because selexipag and prostacyclin analogues do not have identical receptor binding profiles; the defining pharmacological difference is IP receptor selectivity versus broader prostanoid receptor binding, not plasma protein binding differences.
12. Epoprostenol retains a unique position among all approved PAH vasodilatory agents. Which statement correctly identifies what distinguishes it from every other approved PAH drug and the evidence that established this distinction?
A) Epoprostenol is the only PAH vasodilatory agent supported by a randomized controlled trial demonstrating a survival benefit; the pivotal 1996 trial by Barst and colleagues randomized patients with severe PAH to continuous IV epoprostenol versus conventional therapy and demonstrated improvements in 6-minute walk distance, pulmonary hemodynamics, and all-cause mortality — making it the reference standard against which all subsequent PAH therapies are benchmarked
B) Epoprostenol is the only PAH agent approved for both WHO Group 1 PAH and WHO Group 4 CTEPH based on survival data from the CHEST-1 and PATENT-1 trials, distinguishing it from agents approved for Group 1 only
C) Epoprostenol is the only PAH agent with a survival benefit, established by the SERAPHIN trial which demonstrated a 45 percent reduction in the morbidity-mortality composite endpoint including all-cause mortality as the primary driver
D) Epoprostenol is distinguished by being the only PAH vasodilatory agent that raises both cAMP and cGMP simultaneously, activating both PKA and PKG signaling cascades; this dual second-messenger activity accounts for its superior survival benefit over agents that raise only one second messenger
E) Epoprostenol is distinguished from other prostacyclin agents by its oral bioavailability, which enables consistent plasma concentrations without catheter-related infectious complications; the survival benefit was established in the AMBITION trial comparing upfront epoprostenol combination versus monotherapy
ANSWER: A
Rationale:
The 1996 randomized controlled trial by Barst and colleagues enrolled patients with severe primary pulmonary hypertension and compared continuous IV epoprostenol against conventional therapy (anticoagulation, diuretics, oxygen, and vasodilators). The trial demonstrated statistically significant improvements in 6MWD, pulmonary hemodynamics (reduced mPAP and PVR, improved cardiac output), and crucially, a survival benefit — the only PAH therapy to demonstrate reduced all-cause mortality in a prospective randomized trial in the modern treatment era. This survival benefit, combined with epoprostenol's status as the first effective PAH-specific therapy, established it as the reference standard and the preferred parenteral agent for high-risk patients in contemporary guidelines. No other approved PAH vasodilatory agent — including the ERAs, PDE-5 inhibitors, riociguat, or selexipag — has demonstrated a survival benefit in a dedicated randomized trial, though composite morbidity-mortality endpoints have been used in more recent trials.
Option B: Option B is incorrect because CHEST-1 and PATENT-1 were riociguat trials, not epoprostenol trials; riociguat holds the Group 4 CTEPH approval, not epoprostenol.
Option C: Option C is incorrect because SERAPHIN was the macitentan trial; its primary endpoint was a morbidity-mortality composite, and it is not the trial that established epoprostenol's survival benefit; furthermore, the SERAPHIN primary endpoint was driven by worsening events rather than mortality as the dominant component.
Option D: Option D is incorrect because epoprostenol raises cAMP via IP receptor–Gs coupling and does not directly raise cGMP; the cGMP pathway is targeted by PDE-5 inhibitors and riociguat, not by prostacyclin pathway agents.
Option E: Option E is incorrect because epoprostenol is not orally bioavailable — its 2- to 5-minute half-life and rapid degradation at physiological pH make it impossible to deliver orally; it requires continuous IV infusion, and the survival evidence comes from the 1996 Barst trial, not from AMBITION.
13. PAH-specific vasodilators are contraindicated in WHO Group 2 pulmonary hypertension (caused by left heart disease). Which explanation most precisely describes the hemodynamic mechanism by which these agents can cause clinical harm in Group 2 disease?
A) PAH vasodilators cause harm in Group 2 by blocking endothelin receptors in the left ventricular myocardium, reducing cardiac contractility and precipitating acute systolic heart failure; this negative inotropic effect does not occur in Group 1 because the right ventricle is less sensitive to ETA receptor blockade
B) PAH vasodilators cause harm in Group 2 by raising cAMP in pulmonary arterial smooth muscle, which cross-activates sympathetic nerve terminals and raises systemic vascular resistance, worsening left ventricular afterload and precipitating hypertensive crisis
C) PAH vasodilators cause harm in Group 2 by selectively dilating the bronchial arterial circulation rather than the pulmonary arterial bed, redistributing blood flow away from ventilated alveoli and severely worsening ventilation-perfusion mismatch
D) PAH vasodilators cause no harm in Group 2 as long as the pulmonary arterial wedge pressure (PAWP) is below 20 mmHg; the contraindication applies only to patients with PAWP above 25 mmHg where the risk of pulmonary edema is pre-existing
E) In Group 2 pulmonary hypertension, elevated pulmonary pressures reflect backward transmission of elevated left-sided filling pressures through the pulmonary vasculature; PAH vasodilators selectively reduce pulmonary vascular resistance and increase pulmonary blood flow into a left heart that cannot accommodate the increased preload, worsening left ventricular filling pressures, unmasking or precipitating pulmonary edema, and potentially causing hemodynamic deterioration
ANSWER: E
Rationale:
In WHO Group 2 pulmonary hypertension (from left ventricular systolic or diastolic dysfunction, valvular disease, or other left heart pathology), pulmonary hypertension is postcapillary: elevated pulmonary pressures result from backward transmission of elevated left ventricular end-diastolic pressure through the pulmonary venous and capillary bed, reflected as a raised pulmonary arterial wedge pressure (PAWP above 15 mmHg). The pathophysiology is fundamentally different from Group 1 PAH, where pulmonary hypertension is intrinsic to the pulmonary arterial wall. When a PAH-specific vasodilator is administered to a Group 2 patient, it selectively dilates the pulmonary arterial bed — reducing pulmonary vascular resistance and increasing blood flow forward through the lungs — but does not and cannot address the downstream obstruction to left heart filling. The increased pulmonary blood flow encounters an elevated PAWP from the non-compliant or failing left ventricle; this worsens pulmonary venous congestion, raises pulmonary capillary pressure, and can precipitate acute pulmonary edema and hemodynamic deterioration. Several clinical trials of PAH drugs in Group 2 patients have demonstrated increased harm, reinforcing the categorical contraindication.
Option A: Option A is incorrect because PAH vasodilators do not cause significant negative inotropy through ETA blockade in the left ventricular myocardium; the mechanism of harm in Group 2 is hemodynamic — increased pulmonary flow into an incompetent left heart — not direct myocardial depression.
Option B: Option B is incorrect because the mechanism of harm is not sympathetic activation or systemic vasoconstriction; PAH vasodilators reduce pulmonary resistance and do not cross-activate sympathetic pathways in a clinically meaningful way.
Option C: Option C is incorrect because PAH vasodilators act on pulmonary arterial smooth muscle, not bronchial arteries, and the mechanism of harm is pulmonary venous congestion from increased left heart preload, not bronchial blood flow redistribution.
Option D: Option D is incorrect because the contraindication is not defined by a specific PAWP cutoff above 20 or 25 mmHg; any patient with Group 2 PH where pulmonary hypertension is driven by elevated left-sided filling pressures is at risk, and the hemodynamic harm mechanism applies whenever a non-compliant left heart cannot accommodate increased pulmonary inflow.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.